TW201338777A - 用於治療金屬過載之經口調配物 - Google Patents

用於治療金屬過載之經口調配物 Download PDF

Info

Publication number
TW201338777A
TW201338777A TW101146269A TW101146269A TW201338777A TW 201338777 A TW201338777 A TW 201338777A TW 101146269 A TW101146269 A TW 101146269A TW 101146269 A TW101146269 A TW 101146269A TW 201338777 A TW201338777 A TW 201338777A
Authority
TW
Taiwan
Prior art keywords
compound
formula
salt
dosage form
iron
Prior art date
Application number
TW101146269A
Other languages
English (en)
Chinese (zh)
Inventor
Hugh Y Rienhoff
Original Assignee
Ferrokin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48574916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201338777(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrokin Biosciences Inc filed Critical Ferrokin Biosciences Inc
Publication of TW201338777A publication Critical patent/TW201338777A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW101146269A 2011-12-09 2012-12-07 用於治療金屬過載之經口調配物 TW201338777A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568914P 2011-12-09 2011-12-09
US201161568890P 2011-12-09 2011-12-09

Publications (1)

Publication Number Publication Date
TW201338777A true TW201338777A (zh) 2013-10-01

Family

ID=48574916

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101146269A TW201338777A (zh) 2011-12-09 2012-12-07 用於治療金屬過載之經口調配物

Country Status (9)

Country Link
US (1) US8993606B2 (enExample)
EP (1) EP2787994A4 (enExample)
JP (1) JP2015500294A (enExample)
AR (1) AR089122A1 (enExample)
AU (1) AU2012347595A1 (enExample)
BR (1) BR112014013985A2 (enExample)
CA (1) CA2857990A1 (enExample)
TW (1) TW201338777A (enExample)
WO (1) WO2013086312A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140343110A1 (en) 2011-12-16 2014-11-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
EP2970162A1 (en) 2013-03-15 2016-01-20 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
AU2014352780A1 (en) * 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
WO2016176343A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
WO2018104130A1 (en) 2016-12-07 2018-06-14 Lumileds Holding B.V. Flash light emitter with remote communication function
CN114302882A (zh) * 2019-07-19 2022-04-08 威佛（国际）股份公司 用于治疗输血依赖型β-地中海贫血（tdt）的膜铁转运蛋白抑制剂
WO2022157185A1 (en) 2021-01-20 2022-07-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1866296T3 (pl) 2005-04-04 2017-05-31 University Of Florida Research Foundation, Inc. Polieterowe analogi desferritiocyny
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8324397B2 (en) 2007-03-15 2012-12-04 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
NZ605452A (en) * 2008-07-14 2014-05-30 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
BR112012001761A2 (pt) 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
WO2011028255A2 (en) 2009-08-25 2011-03-10 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
US9045440B2 (en) 2010-05-04 2015-06-02 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Also Published As

Publication number Publication date
CA2857990A1 (en) 2013-06-13
US20130225645A1 (en) 2013-08-29
AU2012347595A1 (en) 2014-06-26
US8993606B2 (en) 2015-03-31
JP2015500294A (ja) 2015-01-05
EP2787994A4 (en) 2015-08-26
EP2787994A1 (en) 2014-10-15
WO2013086312A1 (en) 2013-06-13
BR112014013985A2 (pt) 2017-06-13
AR089122A1 (es) 2014-07-30

Similar Documents

Publication Publication Date Title
US12077554B2 (en) CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CN101208344B (zh) (r)-n-甲基纳曲酮、其合成方法以及其药物用途
RU2723642C1 (ru) Соединения метаболита антагониста рецептора ангиотензина ii и ингибитора nep, и способы их получения
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
KR20120115380A (ko) 마이봄선 기능 장애의 치료 방법
JP2009537565A (ja) Ｒ（＋）およびｓ（−）プラミペキソール組成とそれを利用する方法
US8993606B2 (en) Oral formulations for treating metal overload
KR20190077348A (ko) 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
US20200376004A1 (en) Amorphous onapristone compositions and methods of making the same
EP3827831B1 (en) Pharmaceutical composition for preventing or treating nonalcoholic steatohepatitis
JP2015500294A5 (enExample)
KR20250134679A (ko) 라니피브라노르 제형
TW202416974A (zh) 標靶細胞外HSP90(eHSP90)之放射性藥物及其用途
CA3029948A1 (en) Antidiabetic solid pharmaceutical compositions
WO2015101794A1 (en) Pharmaceutical composition
WO2017217071A1 (ja) セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤
KR20180132955A (ko) 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법
WO2017023999A1 (en) Methylsulfonamide derivatives and uses related thereto
US20190224185A1 (en) Preparation of (-)-cocaine hydrochloride
TW201427962A (zh) 脫氮雜去鐵硫辛（ｄｅｓａｚａｄｅｓｆｅｒｒｉｔｈｉｏｃｉｎ）類似物之多晶型形式
RO131477A2 (ro) Capsule gelatinoase moi conţinând citizină